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Abstract. Data on the epidemiology of severe acute respiratory illness (SARI) in adults from low-income, high human
immunodeﬁciency virus (HIV) prevalence African settings are scarce. We conducted adult SARI surveillance in Blantyre,
Malawi. From January 2011 to December 2013, individuals aged ³ 15 years with SARI (both inpatients and outpatients)
were enrolled at a large teaching hospital in Blantyre, Malawi. Nasopharyngeal aspirates were tested for inﬂuenza and
other respiratory viruses by polymerase chain reaction. We estimated hospital-attended inﬂuenza-positive SARI in-
cidence rates and assessed factors associated with inﬂuenza positivity and clinical severity (Modiﬁed Early Warning
Score > 4). We enrolled 1,126 SARI cases; 163 (14.5%) were positive for inﬂuenza. Human immunodeﬁciency virus
prevalence was 50.3%. Annual incidence of hospital-attended inﬂuenza-associated SARI was 9.7–16.8 cases per
100,000 population. Human immunodeﬁciency virus was associated with a 5-fold greater incidence (incidence rate ratio
4.91, 95%conﬁdence interval [CI]: 3.83–6.32).Onmultivariable analysis, femalegender, aswell as recruitment in hot, rainy
season (December to March; adjusted odds ratios (aOR): 2.82, 95%CI: 1.57–5.06) and cool, dry season (April to August;
aOR: 2.47, 95% CI: 1.35–4.15), was associated with inﬂuenza positivity, whereas inﬂuenza-positive patients were less
likely to be HIV-infected (aOR: 0.59, 95%CI: 0.43–0.80) or have viral coinfection (aOR: 0.51, 95%CI: 0.36–0.73). Human
immunodeﬁciency virus infection (aOR: 1.86; 95%CI: 1.35–2.56) and recruitment in hot, rainy season (aOR: 4.98, 95%CI:
3.17–7.81) were independently associated with clinical severity. In this high HIV prevalence population, inﬂuenza was
associated with nearly 15% of hospital-attended SARI. Human immunodeﬁciency virus infection is an important risk
factor for clinical severity in all-cause and inﬂuenza-associated SARI. Expanded access to HIV testing and antiretroviral
treatment, as well as targeted inﬂuenza vaccination, may reduce the burden of SARI in Malawi and other high HIV
prevalence settings.
INTRODUCTION
Pneumonia is an important cause ofmorbidity andmortality
in adults in sub-Saharan Africa.1 However, the burden of se-
vere respiratory illness and the contribution of inﬂuenza and
other respiratory viruses are not well documented in the re-
gion. Lack of diagnostic capacity, similarity of inﬂuenza pre-
sentation with common febrile illnesses such as malaria and
bacterial pneumonia, and prioritization of other high-burden
public health problems are likely contributory factors. A recent
systematic review concluded that most of the sub-Saharan
African countries had insufﬁcient epidemiological data to de-
velop rational strategies for inﬂuenza prevention and control.2
It is, therefore, unsurprising that although the World Health
Organization (WHO) recommends seasonal inﬂuenza vaccine
for high-risk groups, such as young children, pregnant
women, and Human immunodeﬁciency virus (HIV)–infected
individuals,3 few African countries have implemented these
recommendations or have national policies.4
Following the 2009 inﬂuenza A(H1N1) pandemic, respiratory
viral surveillance capacity has increased substantially in
Africa.5 Currently, 23 sub-Saharan African countries contribute
data to the WHO Global Surveillance and Response System.6
Emerging data suggest that inﬂuenza viruses are frequently
detected in mild (6.7–40.4%) and severe (4.6–25.5%) acute
respiratory presentations in the region7 and are associatedwith
a higher mortality compared with developed settings because
of thehighprevalenceofHIV infectionandother comorbidities.8
However, only a handful of studies have focused on adults9,10
and few have comprehensively ascertained HIV status.
Malawi is a low-income country, ranked 170th of 188
countries in the Human Development Index.11 Active surveil-
lance for inﬂuenza and other respiratory viruses was estab-
lished at a large urban teaching hospital in Malawi in January
2011. In this high HIV prevalence and malaria-endemic set-
ting, we aimed to describe the epidemiology and viral etiology
and factors associated with clinical severity and inﬂuenza
positivity among individuals aged ³ 15 yearswith severe acute
respiratory illness (SARI) during 2011–2013.
MATERIALS AND METHODS
Study site and setting. Malawi has hot rainy (mean tem-
perature > 22C and rainfall > 100 mm; December to March),
cool and dry (mean temperature < 22C and rainfall < 50 mm;
April to August), and hot and dry (mean temperature > 22C
and rainfall < 50 mm; September to November) seasons. The
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Queen Elizabeth Central Hospital (QECH) is the only govern-
ment inpatient facility providing free health care to the 1.3
million residents of Blantyre District. Consequently, most in-
dividuals requiring hospitalization from this community will
present to QECH. Human immunodeﬁciency virus prevalence
in Blantyre is estimated at 17.7%,12 but up to 74% of patients
admitted to the QECH medical wards are HIV infected.13
Malaria is endemic in Malawi (peak transmission months
January to June), and malaria rapid diagnostic test (RDT)
positivity is 8% among adult inpatients at QECH.14 Lower
respiratory tract infections are the commonest cause of
medical admission at QECH.13 There is no national inﬂuenza
vaccination policy in Malawi. A WHO-led inﬂuenza A(H1N1)
pdm09 vaccine campaign targeting health-care workers and
pregnant women occurred in 2010.15
Study procedures. Patients aged 15 years and older pre-
senting to the QECH Emergency Department during surveil-
lance hours (8 AM to 3 PM on weekdays) were screened for
study eligibility. Consecutive patients from the start of the day
fulﬁlling the SARI case deﬁnition were recruited (maximum
four per day). Study staff collected demographic, clinical, and
risk factor information using structured questionnaires and
obtained nasopharyngeal aspirates and blood specimens for
malaria and HIV testing.
SARI was deﬁned as 1) an acute respiratory illness with
symptom onset < 7 days, 2) reported or recorded fever (³ 38C),
3) cough or sore throat, and 4) shortness of breath or difﬁculty
breathing. In our resource-limited setting, patientswith severe
illness requiring admission were often sent home. Therefore,
hospital attendance (not admission) was required for study
enrolment.
Laboratory procedures. The processing of respiratory
specimens has been described previously.16 In brief, naso-
pharyngeal aspirates were stored at −80C in Universal
Transport Medium (Copan, Brescia, Italy). These were
batch-tested for inﬂuenza A and B by real-time reverse
transcription–polymerase chain reaction (rRT-PCR) using the
CDC human inﬂuenza reverse transcription–PCR diagnostic
panel (CDC Inﬂuenza Division, http://www.cdc.gov/ncird/ﬂu.
html). Inﬂuenza-positive specimens were subtyped using
the CDC rRT-PCR protocol. The FTD respiratory pathogens
33 kit (Fast-trackDiagnostics Ltd., Luxembourg, http://www.
fast-trackdiagnostics.com) was used to detect coronavi-
ruses OC43, NL63, HKU1, and 229E; parainﬂuenza viruses
1–4; respiratory syncytial viruses (RSV) A and B; enterovirus;
human metapneumovirus; rhinovirus; adenovirus; and
bocavirus. Samples with a Ct value < 40 were recorded as
positive.
Human immunodeﬁciency virus testing (Alere Determine™
HIV-1/2, Waltham, MA, and Trinity Biotech Uni-Gold™ HIV,
Bray,Co.,Wicklow, Ireland)wasperformedaccording toWHO
guidelines.17Rapid diagnostic test formalaria (ParacheckPf®,
Orchid Biomedical Systems, Bamboli, Goa, India) was also
performed in accordance with the manufacturer’s instructions.
Climatic data. Data on rainfall (millimeters), temperature
(degree Celsius), and relative humidity (percentage) were
obtained from theMalawi Department of Climate Change and
Meteorological Services for 2011–2013.
Statistical analysis. Analysis was performed using Stata
(Version 12.0; StataCorp Limited, College Station, TX). Monthly
mean temperature, rainfall, and relative humidity were plotted
against the number and proportion of inﬂuenza-positive SARI
cases over the surveillance period to assess the association
between climatic variations and inﬂuenza activity.
Numerators for minimum adult inﬂuenza-associated SARI
incidence estimates were generated from the number of en-
rolled SARI with a positive inﬂuenza PCR that resided in the
Blantyre district and adjusted for non-enrolment (during
weekends and outside of surveillance hours on weekdays) by
multiplying by the reciprocal of the proportion of recruited
cases among all SARI cases attending the emergency de-
partment. The latter was recorded on the Surveillance Pro-
gram of Inpatients and Epidemiology (SPINE) electronic data
collection system.13 The annual incidence of hospital-
attended inﬂuenza-positive SARI per 100,000 persons was
estimated using the adjusted number of medically attended
inﬂuenza-positive SARIs, divided by the census estimates of
Blantyre District population aged ³ 15 years for each year,18
and multiplied by 100,000. Incidence by HIV status was also
calculated for individuals aged 15–49 years (in whom HIV
prevalence is available18). Human immunodeﬁciency virus–
associated incidence rate ratios (IRRs) were calculated by
dividing the incidence in HIV-infected strata by the incidence
in HIV-uninfected strata. 95% Conﬁdence intervals (CIs) for
incidenceestimates andHIV-associated IRRswere calculated
using the Poisson distribution.
Logistic regression was used to calculate odds ratios (OR)
and 95%CIs to compare clinical variables between inﬂuenza-
positive and inﬂuenza-negative patients. Multivariable logistic
regression models were developed for two outcomes of in-
terest: 1) inﬂuenza positivity and 2) clinical severity (deﬁned as
Modiﬁed Early Warning Score (MEWS) > 4).19 Modiﬁed early
warning score is a simple physiological score based on ﬁve
parameters (respiratory rate, heart rate, systolic blood pres-
sure, temperature, and conscious level). It has been widely
used in developed health-care settings to identify patients at
risk of deterioration. A score of greater than 4 has been shown
tobepredictive of inpatientmortality in bothwell-resourced19,20
and African settings.21,22 Covariates with a P value of < 0.2 on
univariable analysis, in addition to age, gender, and year of
surveillance considered a priori confounders, were assessed
for signiﬁcance using backward stepwise selection. Odds
ratios and 95% CIs were reported. Factors with 2-sided P val-
ues of < 0.05 were considered signiﬁcant.
Ethics approval. Ethical approval for this study was
obtained from the University of Malawi College of Medicine
Research Ethics Committee (P.07/10/958), Liverpool School
of Tropical Medicine (10.76), and the CDC through an ethical
reliance. All participants provided written informed consent.
RESULTS
Demographic characteristics. Between January 2011
and December 2013, 1,126 SARI cases aged 15 years and
older were enrolled (Table 1). The median age was 33 years
(interquartile range 26–42 years) and 489 (43.4%) were male.
Of 1,109 patients with available HIV status (98.5%), 558
(50.3%) were HIV infected. Thirteen individuals reported re-
ceipt of inﬂuenza vaccination in the previous year.
Viruses detected among SARI patients. One or more re-
spiratory viruses were identiﬁed in 533 (47.3%) enrolled SARI
cases (Table 1). Inﬂuenza viruses were detected in 163
(14.5%) SARI cases. When tested for the extended panel of
respiratory viruses (N = 1,123) (Figure 1), rhinovirus was
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detected in 149 (13.3%), coronavirusOC43 in 49 (4.4%), RSV in
48 (4.2%), and adenovirus in 47 (4.2%). Inﬂuenza A and B were
detectedmore frequently inHIV-uninfected than inHIV-infected
SARI cases (inﬂuenza A, 12.0% versus 8.2%; inﬂuenza B 6.0%
versus3.1%;Supplemental Table 1),whereas theprevalence of
other respiratory viruses did not differ by HIV status.
A single virus was isolated in 253 (22.5%) patients, whereas
154 (13.7%) individuals had twoormore viruses detected. The
highest proportion of viral co-detection was observed for
bocavirus (21/24, 87.5%) and enterovirus (27/32; 84.4%),
whereas the lowest proportion was observed in inﬂuenza A
(26/108; 24.1%).
Seasonality of inﬂuenza virus and malaria. Among the
163 inﬂuenza-positive SARI cases, 61 (37.2%) were inﬂuenza
A(H1N1)pdm09, 47 (28.7%) were inﬂuenza A(H3N2), and 59
(30.5%) were inﬂuenza B. Three cases had inﬂuenza A and B
coinfection and one inﬂuenza A sample was unsubtyped.
Figure 2 illustrates the temporal distribution of inﬂuenza types
and subtypes, as well as malaria RDT positivity. There were
annual cyclesof inﬂuenzaactivity, but timingof peakdetection
varied year to year. In 2011, inﬂuenza activity had a bimodal
peak—in April and July. In 2012, inﬂuenza was detected be-
tween March and June only. By contrast, inﬂuenza was de-
tected throughout 2013 but peaked in January and February.
Peaks in inﬂuenza activity coincided with months with high
relative humidity, but there was no correlation with rainfall or
temperature (Supplemental Figure 1A–C). Inﬂuenza A(H1N1)
pdm09, A(H3N2), and inﬂuenza B circulated in all 3 years; in-
ﬂuenza A(H1N1)pdm09 was the predominant strain in 2011
(39.1%) and 2013 (49.4%), whereas inﬂuenza A(H3N2) was
the most prevalent in 2012 (48.6%).
Of 911 SARI cases with available malaria RDT result, 28
(3.1%) were positive. There was no correlation between in-
ﬂuenza and malaria activity (Figure 2). None of the cases with
malaria were positive for inﬂuenza.
Incidence estimates for hospital-attended inﬂuenza-
positive SARIs. The mean annual incidence of hospital-
attended inﬂuenza-positive SARI per 100,000 for Blantyre
residents aged 15 years and older was 14.4 per 100,000 (95%
CI: 12.9–16.0) [16.8 (95% CI: 13.8–19.8) in 2011, 9.7 (95%CI:
7.4–11.9) in 2012, and 16.9 (95% CI: 140–19.8) in 2013].
Among individuals aged 15–49 years, the mean annual in-
cidence of hospital-attended inﬂuenza-positive SARI in HIV-
infected adults was 46.2 (95%CI: 37.5–56.3) per 100,000 and
TABLE 1
Characteristics of adult patients with SARI, Blantyre, Malawi,
2011–2013
Characteristic SARI cases (N = 1,126) n (%)
Demographic characteristics
Male 489 (43.4)
Age group (years)
15–24 231 (20.5)
25–34 419 (37.2)
35–44 251 (22.3)
³ 45 225 (20.0)
Underlying medical conditions
HIV-positive* 558 (50.3)
Pregnant† 19/637 (3.0)
Current smoker 29 (2.8)
Antibiotics in the past 2 weeks 482 (46.5)
Reported inﬂuenza vaccination
in the past year
13 (1.2)
Infectious agent identiﬁed
Inﬂuenza virus (any type) 163 (14.5)
Inﬂuenza A
H1N1pdm09 61 (37.4)
H3N2 47 (28.8)
Unsubtyped‡ 1 (0.6)
Inﬂuenza B 50 (30.7)
Inﬂuenza A & B 3 (1.8)
Any virus detected§ 533 (47.3)
³ 2 viruses detected 154 (13.6)
Malaria RDT positive 28/911 (3.1)
HIV = human immunodeﬁciency virus; RDT = rapid diagnostic test; SARI = severe acute
respiratory illness.
* HIV status–available for 1,109 patients.
†Pregnancy status established by self-report.
‡ Inﬂuenza A sample with cycle threshold values £ 40 that could not be subtyped.
§ Infection with at least one of inﬂuenza; adenovirus; bocavirus; coronavirus OC43, NL63,
229E and HKU1; enterovirus; human metapneumovirus; parainﬂuenza virus 1, 2, 3, and 4;
rhinovirus, or respiratory syncytial virus.
FIGURE 1. Respiratory viruses* detected in adults with severe acute respiratory illness (SARI), Blantyre, Malawi, 2011–2013. hMPV = human
metapneumovirus; RSV = respiratory syncytial virus. *Respiratory viruses in the 33-pathogen multiplex polymerase chain reaction (PCR) include
adenovirus, bocavirus, coronaviruses (OC43,NL63, 229EandHKU1), enterovirus, humanmetapneumovirus, parainﬂuenza viruses 1–4, respiratory
syncytial virus, and rhinovirus. This ﬁgure appears in color at www.ajtmh.org.
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9.4 (95% CI: 8.1–10.9) per 100,000 in HIV-uninfected adults
(IRR: 4.92, 95% CI: 3.83–6.31).
Factors associated with inﬂuenza positivity in
SARI patients. Compared with inﬂuenza-negative patients, a
higher proportion of inﬂuenza-positive SARI patients reported
headache (90.1 versus 83.6%, OR: 1.79, 95%CI: 1.02–3.13,
P = 0.04). No other clinical feature differences by etiology
were found (see Supplemental Table 2).
In the multivariable analysis (Table 2), female gender was
associated with increased odds of inﬂuenza positivity
compared with male gender (adjusted OR [aOR]: 1.57 (95%
CI: 1.10–2.26). Greater inﬂuenza activity was observed in the
hot, rainy season (17.5%; aOR: 2.82, 95%CI: 1.57–5.06) and
the cold, dry season (16.5%; aOR: 2.37, 95%CI: 1.35–4.15),
compared with the hot, dry season (6.7%). Furthermore,
inﬂuenza positivity was inversely associated with HIV in-
fection (aOR: 0.53, 95% CI: 0.36–0.76, P < 0.001) and co-
detection with another respiratory virus (aOR: 0.46, 95% CI:
0.31–0.70, P < 0.001). Small numbers prohibited the evalu-
ation of speciﬁc viral co-detection combinations with
inﬂuenza.
Factors associated with clinical severity. We found that
238 of 1,126 patients with SARI (21.1%) had clinically severe
disease (MEWS > 4). In multivariable analysis (Table 3), HIV
infection was associated with a nearly 2-fold increase in clin-
ical severity (aOR: 1.86, 95% CI: 1.35–2.56). SARI cases
recruited in the hot, rainy season had ﬁve times increased
odds of clinical severity, compared with those recruited in the
hot, dry season (aOR: 4.98, 95% CI: 3.17–7.81). A higher
proportion of clinically severe cases was also seen among
cases recruited in 2011 (31.1 versus 17.9%, aOR: 2.31, 95%
CI: 1.59–3.36, compared with cases recruited in 2013). In-
ﬂuenza infection was not associated with severe clinical pre-
sentation, nor were infection with other respiratory viruses, or
viral coinfection.
Among the 163 inﬂuenza-positive SARI cases, 40 (24.5%)
had a MEWS > 4. Those infected with inﬂuenza A(H1N1)
pdm09 subtype were signiﬁcantly associated with clinical
severity (64.1%; aOR: 5.40, 95% CI: 1.88–15.53) compared
with those infected with inﬂuenza B (20.5%; aOR: 1.55, 95%
CI: 0.47–5.06) and inﬂuenza A(H3N2) (15.4%; baseline). Hu-
man immunodeﬁciency virus infection also predicted severity
among inﬂuenza-positive SARI cases (38.3% versus 16.7%;
aOR: 3.73, 95% CI: 1.65–8.41) (Supplemental Table 3).
DISCUSSION
Comprehensive hospital-based sentinel surveillance in our
high HIV prevalence, malaria-endemic African setting has
identiﬁed inﬂuenza as an important contributor to SARI in
adults, substantiating data from other African studies.9,10 In
the immediate post-pandemic period, inﬂuenza A(H1N1)
pdm09was thepredominant strain inMalawi in 2011and2013
andwas associated with increased clinical severity compared
with other subtypes. Inﬂuenza activity corresponded to
months with higher relative humidity, but not with malaria
activity. Among adultswith SARI, female gender, in addition to
recruitment in hot, rainy and cool, dry seasons, were associ-
ated with inﬂuenza positivity. Although HIV-infected adults
with SARI were more likely to have an alternative etiology to
inﬂuenza, HIV-infected adults aged 15–49 years had a 5-fold
greater incidence of hospital-attended inﬂuenza-positive
SARI compared with HIV-uninfected adults. Furthermore,
HIV infection predicted clinical severity in all-cause SARI and
inﬂuenza-associated SARI.
The estimated annual incidence of hospital-attended
inﬂuenza-positive SARI ranged from 9.7 to 16.9 per 100,000
adult population, similar to that reported in rural Kenya
(0.3/1,000)23 but substantially lower than estimatesbyanother
Kenyanstudy (2.8/100 for inﬂuenzaAand0.2/100 for inﬂuenza
FIGURE2. Seasonality of inﬂuenza for adultswith severeacute respiratory illness (SARI),Blantyre,Malawi, 2011–2013.Thisﬁgureappears in color
at www.ajtmh.org.
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B9) and a South African study (71–260/100,000 [in HIV-
infected persons] and 5–44/100,000 [in HIV-uninfected per-
sons]).24 This wide variation could be due to geographical and
seasonal differences in disease burden, but is also likely at-
tributable to varying methodologies and case deﬁnitions, in
addition to differing health-seeking behavior and thresholds
for hospital admission. Furthermore, the latter two studies
included children aged 5–14 years, a group that typically has
higher rates of inﬂuenza infection.9,24 It is important to stress
that our incidence estimates represent minimum estimates
because our surveillance only detected persons accessing
care at QECH. A small proportion of patients may have pre-
sented to a traditional healer or to one of the two private
hospitals in Blantyre; SARI cases may not consider their
symptoms severe enough to warrant care; they may be too ill
or too poor to attend, or may have died before presentation.25
Human immunodeﬁciency virus infection, identiﬁed in more
than 50% of adults with SARI, was the sole individual risk
factor associated with increased clinical severity. Indeed,
several African adult pneumonia cohorts have reported a high
prevalenceofHIV infection (52–94%).26–28Our result supports
ﬁndings from others that HIV is an important driver of severe
respiratory infection,29 including inﬂuenza, in sub-Saharan
Africa.
Inﬂuenza was less commonly identiﬁed in HIV-infected
compared with HIV-uninfected SARI cases. This likely reﬂects
the different spectra of organisms affectingHIV-infected adults,
with greater relative contribution of opportunistic pathogens
such as Mycobacterium tuberculosis, Pneumocystis jirovecii,
and Streptococcus pneumoniae, rather than a lower absolute
risk.This hasalsobeendescribed inHIV-infectedchildren30and
adults10 in South Africa. In fact, after taking into account pop-
ulation denominators, HIV-infected adults aged 15–49 years
had a 5-fold greater incidence of inﬂuenza-positive SARI than
HIV-uninfected adults. Having comprehensively ascertained
HIV status, our study corroborates with studies in Malawi,
Kenya, and South Africa that have identiﬁed HIV as amajor risk
factor for inﬂuenza burden25 and severe disease.24,31,32 These
results suggest that early HIV testing and expanded access to
antiretroviral treatment, in addition to targeted inﬂuenza vacci-
nation, could potentially have a substantial impact on burden of
SARI in urban Blantyre and other similar high HIV prevalence
settings. Annual inﬂuenza vaccination is recommended for
HIV-infected individuals.3 Inﬂuenza vaccination in HIV-infected
adults is safe and effective (pooled efﬁcacy 85%),33 but in-
ﬂuenza vaccines are currently unavailable in most African
countries.4,34
SARI cases recruited in hot, rainy season were associated
with a 5-fold increased odds of clinical severity, compared
with those recruited in the hot, dry season. This was also
observed in our pediatric surveillance.16 The reason for this is
unclear but could be related to other unmeasured infections
(we were unable to determine the presence of bacterial path-
ogens in our SARI cases), seasonal patterns of health-care utili-
zation, and seasonalmalnutrition. The hot, rainy season inMalawi
coincideswith the “lean” season before harvest.35 A recent case-
control study inMalawi identiﬁed food insecurityasa risk factor for
inﬂuenza severity,31 thus supporting our latter hypothesis.
TABLE 2
Factors associated with inﬂuenza PCR positivity in adults with SARI, Queen Elizabeth Central Hospital, Blantyre, Malawi, 2011–2013
Characteristic Overall
Inﬂuenza virus
negative, N (%)
Inﬂuenza virus
positive, N (%)
Univariable* Multivariable*†
OR (95% CI) P value* OR (95% CI) P value*
Gendera
Male 489 431 (88.1) 58 (11.9) Ref – – –
Female 636 532 (83.5) 105 (16.5) 1.47 (1.04–2.07) 0.03 1.57 (1.10–2.26) 0.01
Age group (years)
15–24 231 191 (82.7) 40 (17.3) 1.37 (0.89–2.11) 0.36 1.23 (0.78–1.95) 0.68
25–34 419 359 (85.7) 60 (14.3) 1.10 (0.75–1.60) – 1.06 (0.71–1.58) –
³ 35 476 413 (86.8) 63 (13.2) Ref – Ref –
Year of surveillance
2011 251 205 (81.7) 46 (18.3) 2.12 (1.32–3.41) – 2.85 (1.72–4.71) –
2012 366 331 (90.4) 35 (9.6) Ref – Ref –
2013 509 427 (83.9) 82 (16.1) 1.82 (1.19–2.77) 0.003 1.84 (1.17–2.87) < 0.001
Season of recruitment
December–March
(hot and rainy)
348 287 (82.5) 61 (17.5) 2.98 (1.71–5.17) < 0.001 2.82 (1.57–5.06) < 0.001
April–August (cool and dry) 508 424 (83.4) 84 (16.5) 2.77 (1.63–4.72) – 2.37 (1.35–4.15) –
September–November
(hot and dry)
270 252 (93.3) 18 (6.7) Ref – Ref –
HIV status
Negative 551 455 (82.6) 96 (17.4) Ref – Ref –
Positive 558 498 (82.3) 60 (10.8) 0.57 (0.40–0.81) 0.002 0.53 (0.36–0.76) < 0.001
Medical history
Malaria RDT—negative 883 745 (84.3) 138 (15.6) – – – –
Positive 28 28 (100) 0 (0) – – – –
Recent antibiotics—no 556 474 (85.2) 82 (14.8) Ref – – –
Yes 481 411 (85.4) 70 (14.6) 0.98 (0.70–1.39) 0.93 – –
Current smoking—no 1,019 868 (85.1) 151 (14.8) Ref – – –
Yes 29 28 (96.5) 1 (3.5) 0.21 (0.03–1.52) 0.12 – –
Co-detection with other respiratory virus(es)
No 717 593 (82.7) 124 (17.3) Ref – Ref –
Yes 409 370 (90.5) 39 (9.5) 0.50 (0.34–0.74) < 0.001 0.46 (0.31–0.70) < 0.001
CI = conﬁdence interval; HIV = human immunodeﬁciency virus; OR = odds ratio; PCR = polymerase chain reaction; RDT = rapid diagnostic test; SARI = severe acute respiratory illness.
* Logistic regression.
†Backward stepwise approach, including a priori confounders (age, gender, HIV status, and year of surveillance) and all variables with P < 0.20 in univariate analysis
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TABLE 3
Factors associated with clinical severity (MEWS > 4) in adults with SARI, Blantyre, Malawi, 2011–2013
Characteristic
Number of cases with
clinical severity N (%)
Univariable* Multivariable*†
OR (95% CI) P value OR (95% CI) P value
Gender
Male 105/489 (21.5) Ref – Ref –
Female 133/636 (20.9) 0.97 (0.72–1.29) 0.82 0.93 (0.69–1.27) 0.65
Age group (years)
15–24 46/231 (19.9) Ref – Ref –
25–34 87/419 (20.8) 1.05 (0.71–1.57) – 0.82 (0.53–1.26) –
³ 35 105/476 (22.1) 1.11 (0.81–1.51) 0.80 0.96 (0.63–1.46) 0.55
Year of surveillance
2011 78/251 (31.1) 2.07 (1.46–2.94) 0.001 2.31 (1.59–3.36) < 0.001
2012 69/366 (18.9) 1.07 (0.75–1.51) – 1.19 (0.82–1.72) –
2013 91/509 (17.9) Ref – Ref –
Season
December–March (hot and rainy) 125/348 (35.9) 4.32 (2.80–6.67) – 4.98 (3.17–7.81) < 0.001
April–August (cool and dry) 82/508 (16.1) 1.48 (0.95–2.31) – 1.66 (1.05–2.63) –
September–November (hot and dry) 31/270 (11.5) Ref – Ref –
HIV status
Negative 91/551 (16.5) Ref – Ref –
Positive 143/558 (25.6) 1.74 (1.30–2.34) < 0.001 1.86 (1.35–2.56) < 0.001
Medical history
Pregnancy–No 131/618 (21.2) Ref – – –
Yes 2/19 (10.5) 0.44 (0.10–1.92) 0.27 – –
Recent antibiotics–No 134/548 (24.5) Ref – – –
Yes 101/483 (20.9) 0.82 (0.61–1.10) 0.19 – –
Current smoker—no 224/946 (23.7) Ref – – –
Yes 14/102 (13.7) 0.25 (0.06–1.04) 0.06 – –
Malaria RDT—Negative 213/883 (24.1) Ref – – –
Positive 6/28 (21.4) 0.86 (0.34–2.14) 0.74 – –
Inﬂuenza—negative 198/962 (20.6) Ref – – –
Positive 40/163 (24.5) 1.25 (0.85–1.85) 0.25 – –
Viral co-infections
No 198/976 (20.3) Ref – – –
Yes 40/150 (26.7) 1.37 (0.93–2.03) 0.11 – –
Other respiratory viruses
Adenovirus—negative 228/1,076 (21.2) Ref – – –
Positive 10/47 (21.3) 1.01 (0.49–2.05) 0.99 – –
Bocavirus—negative 232/1,099 (21.1) Ref – – –
Positive 6/24 (25.0) 1.25 (0.49–3.17) 0.65 – –
Coronavirus
OC43—negative 225/1,074 (21.0) Ref – – –
Positive 13/49 (26.5) 1.36 (0.71–2.61) 0.35 – –
NL63—negative 227/1,086 (20.9) Ref – – –
Positive 11/37 (29.7) 1.60 (0.78–3.29) 0.20 – –
229E—negative 227/1,088 (20.9) Ref – – –
Positive 11/35 (31.4) 1.74 (0.84–3.60) 0.14 – –
HKU1—negative 220/1,063 (20.7) Ref – – –
Positive 7/40 (17.5) 0.81 (0.35–1.86) 0.62 – –
Enterovirus—negative 236/1,091 (21.6) Ref – – –
Positive 2/32 (6.3) 0.24 (0.06–1.02) 0.05 – –
hMPV—negative 224/1,089 (20.6) Ref – – –
Positive 14/34 (41.2) 2.70 (1.34–5.44) 0.005 – –
Parainﬂuenza virus
1—Negative 230/1,095 (21.0) Ref – – –
Positive 8/28 (28.6) 1.50 (0.65–3.46) 0.34 – –
2—Negative 231/1,105 (20.9) Ref – – –
Positive 7/18 (38.9) 2.40 (0.92–6.28) 0.07 – –
3—Negative 234/1,100 (21.3) Ref – – –
Positive 4/23 (17.4) 0.78 (0.26–2.31) 0.65 – –
4—Negative 233/1,095 (21.3) Ref – – –
Positive 5/28 (17.9) 0.80 (0.30–2.14) 0.66 – –
RSV—negative 226/1,075 (21.0) Ref – – –
Positive 12/47 (25.0) 1.25 (0.64–2.45) 0.51 – –
Rhinovirus—negative 201/974 (20.6) Ref – – –
Positive 37/149 (24.8) 1.27 (0.85–1.90) 0.24 – –
CI=conﬁdence interval;HIV=human immunodeﬁciency virus;MEWS=modiﬁedearlywarning score;OR=odds ratio; RDT= rapiddiagnostic test; RSV= respiratory syncytial virus;SARI=severe
acute respiratory infection.
* Logistic regression.
†Backward stepwise approach, including a priori confounders (age, gender, HIV status, and year of surveillance) and all variables with P < 0.20 in univariate analysis.
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We identiﬁed at least one respiratory virus in nearly half of
all SARI cases, higher than that described in South African
adults,10 and in developed settings.36,37 Viral coinfections
were common, occurring in 14%of adult SARI cases.We also
found a nonsigniﬁcant trend toward increased severity in
adults with viral coinfection (26.7% versus 20.3% with
MEWS>4,P= 0.11). There is growing recognition that viruses
other than inﬂuenza, such as rhinovirus, adenovirus, hMPV,
andparainﬂuenza viruses, can cause clinically severedisease.
However, whereas the detection of inﬂuenza, RSV, and hMPV
in adults with SARI likely indicates an etiologic role,38,39 the
presence of other respiratory viruses is of uncertain signiﬁ-
cance, particularly as we did not enroll accompanying con-
trols. Further understanding of the interactions and contribution
of these viruses to severe respiratory diseasewill help to narrow
the focus on pertinent targets for vaccine and antiviral
development.
Our study has a number of limitations. First, we conducted
single-site hospital-based surveillance. Although there are no
other large inpatient facilities inBlantyre, we have not sampled
from elsewhere in Malawi. Second, limiting recruitment to the
ﬁrst four cases of the day could have resulted in selection bias
because individuals who present to hospital at different times
of the day may have varying characteristics, such as health-
seeking behavior or distance of residence from hospital. Third
as discussed earlier, patients with SARI could have sought
health care in facilities other than QECH, leading to an un-
derestimation of our inﬂuenza-associated SARI rates. Under-
ascertainment of SARI cases and resultant underestimation of
incidence were also possible if SARI cases were not system-
atically recorded onto SPINE. Fourth, although we had near-
complete ascertainment of HIV status (98.5%), data on CD4+
cell count and antiretroviral treatment status were not avail-
able. Comorbidities were also poorly recorded; thus, we were
unable to evaluate chronic lung disease as a potential risk
factor for inﬂuenzaor adjust for underlying comorbidities in the
multivariable analysis for clinical severity. Last, data on hos-
pitalization and mortality were not systematically captured.
Instead, we used the MEWS score as a surrogate marker for
clinical severity. The score has beenwidely used in developed
health-care settings to identify patients at risk of deteriora-
tion, and a threshold of greater than four is predictive of in-
patient mortality.19 It has also been validated in other African
settings.21,22
This study provides a baseline for understanding the
complexities of SARI epidemiology in adults in Malawi and
other similar settings. In this high HIV prevalence setting,
respiratory viruses were commonly identiﬁed in adults with
SARI and inﬂuenza has a prominent etiological role. Human
immunodeﬁciency virus–infected adults are at particular risk
of severe disease and have a higher burden of inﬂuenza-
associated SARI than HIV-uninfected individuals. Ongoing
surveillance for inﬂuenza and other respiratory viruses, with
speciﬁc focus on severe disease in high-risk groups such as
HIV-infected individuals and pregnant women, and greater
effort to capture outcome data are critical to further char-
acterize disease burden in these high-risk groups to inform
public policy decisions. Improved HIV testing and early ART
initiation, as well as targeted inﬂuenza vaccination could
potentially substantially reduce the burden of SARI inMalawi
and other sub-Saharan African countries with high HIV
prevalence.
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